Literature DB >> 18301317

The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver.

Jung Im Kim1, Jeong Min Lee, Jin Young Choi, Young Kon Kim, Se Hyung Kim, Jae Young Lee, Joon Koo Han, Byung Ihn Choi.   

Abstract

OBJECTIVES: To evaluate the value of 1-hour delayed phase imaging (DPI) of gadobenate dimeglumine (Gd-BOPTA)-enhanced MR imaging for the characterization of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) in patients with cirrhosis.
MATERIALS AND METHODS: A total of 37 patients with 42 HCCs and 13 DNs were included in this study and all lesions were histopathologically confirmed except for 15 HCCs. T1-weighted 3-dimensional gradient-echo images were acquired before, immediately after (30, 60, 180 s), and 1 hour after bolus injection of gadobenate dimeglumine at a dose of 0.1 mmol/kg. The lesions were classified as isointense, hypointense, or hyperintense compared with the surrounding liver parenchyma on DPI for qualitative assessment. We performed quantitative analyses of the contrast-to-noise ratio (CNR) and of the relative contrast enhancement of the lesion on the DPI.
RESULTS: In the qualitative analysis, among 42 HCCs, 30 (71.4%) were hypointense on DPI, and 10 (23.8%) and 2 (4.8%) were isointense and hyperintense, respectively; only 1 of 13 DNs (7.7%) was hypointense and 10 (76.9%) and 2 (15.4%) were isointense and hyperintense, respectively. In contrast, 25 HCCs (71.4%) of 35 hypervascular HCCs were hypointense on DPI, and no hypervascular DN (0/7) was hypointense with statistical significance (P = 0.0007). When we considered the hypointensity of the hepatic lesions on delayed phase as a sign of HCC in cirrhotic liver, our results gave a sensitivity of 71.4% and a specificity of 91.7%. In the quantitative analysis, the mean CNR of the HCCs and the DNs on the 1-hour DPI was -6.32 +/- 6.27 and -0.07 +/- 3.28, respectively; the difference between the HCCs and the DNs was significant (P < 0.05).
CONCLUSIONS: Delayed gadobenate dimeglumine-enhanced MR imaging allows improved characterization of HCC in cirrhotic liver. The relative hypointensity to adjacent normal liver parenchyma is a reliable predictor that this lesion favors HCC rather than DN in cirrhotic liver.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18301317     DOI: 10.1097/RLI.0b013e31815d6929

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  17 in total

1.  Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.

Authors:  J Hwang; S H Kim; M W Lee; J Y Lee
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

2.  High resolution navigated three-dimensional T₁-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla.

Authors:  Scott K Nagle; Reed F Busse; Anja C Brau; Jean H Brittain; Alex Frydrychowicz; Yuji Iwadate; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-05-30       Impact factor: 4.813

3.  Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid.

Authors:  Alex Frydrychowicz; Scott K Nagle; Sharon L D'Souza; Karl K Vigen; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2011-07-12       Impact factor: 4.813

4.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

Review 5.  [Radiological diagnosis of primary hepatic malignancy].

Authors:  Benjamin Henninger; Johannes Petersen; Werner Jaschke
Journal:  Wien Med Wochenschr       Date:  2013-02-08

6.  [Rational imaging of hepatocellular carcinoma. The challenge of multimodal diagnostic criteria].

Authors:  A Kircher; G Bongartz; E M Merkle; C J Zech
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

7.  Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study.

Authors:  Masakatsu Tsurusaki; Keitaro Sofue; Hiroyoshi Isoda; Masahiro Okada; Kazuhiro Kitajima; Takamichi Murakami
Journal:  J Gastroenterol       Date:  2015-07-01       Impact factor: 7.527

Review 8.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.

Authors:  Yulri Park; Seong Hyun Kim; Seung Hoon Kim; Yong Hwan Jeon; Jongmee Lee; Min Ju Kim; Dongil Choi; Won Jae Lee; Heejung Kim; Ji Hyun Koo; Hyo Keun Lim
Journal:  Korean J Radiol       Date:  2010-06-21       Impact factor: 3.500

10.  Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging.

Authors:  Michele Di Martino; Gianmaria De Filippis; Adriano De Santis; Daniel Geiger; Maurizio Del Monte; Concetta Valentina Lombardo; Massimo Rossi; Stefano Ginanni Corradini; Gianluca Mennini; Carlo Catalano
Journal:  Eur Radiol       Date:  2012-11-18       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.